Journal
SEMINARS IN THROMBOSIS AND HEMOSTASIS
Volume 40, Issue 3, Pages 313-318Publisher
THIEME MEDICAL PUBL INC
DOI: 10.1055/s-0034-1370769
Keywords
bleeding; venous thromboembolism; anticoagulation; survival; chemotherapy; cancer
Categories
Funding
- National Centers for Advancing Translational Science [NIH TR000002]
Ask authors/readers for more resources
Venous thromboembolism (VTE) is a common complication of malignancy. This is related to the underlying cancer and thrombogenic effects of various therapies. Compared with VTE in patients without malignancies, cancer-associated thrombosis is associated with increased mortality, recurrence, and bleeding while on anticoagulants. These worse outcomes are due to a complex interplay between the underlying cancer, host response, antitumor therapies, and interactions between anticoagulants and cancer drugs. Primary prevention of VTE may decrease morbidity and possibly even improve cancer-related survival, but studies to date have not clearly identified a patient population that might be of most benefit nor consistently shown a survival benefit to anticoagulation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available